We also need to consider the integration of this treatment as a neoadjuvant for stage III melanoma with the following design: anti-PD-1 therapy in the neoadjuvant setting followed by surgery and a combination of TILs + anti-PD-1 therapy for non-CR patients. This evidence concerns the gene PDCD1 and melanoma.